UBS Group
TXG icon

UBS Group’s 10x Genomics TXG Stock Holding History

UBS Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Buy
494,868
+106
+0% +$2.78K ﹤0.01% 2742
2026
Q1 		$10.5M Sell
494,762
-366,238
-43% -$7.32M ﹤0.01% 3273
2025
Q4 		$14M Buy
861,000
+102,020
+13% +$1.54M ﹤0.01% 2941
2025
Q3 		$8.87M Sell
758,980
-157,997
-17% -$2.06M ﹤0.01% 3434
2025
Q2 		$10.6M Buy
916,977
+84,189
+10% +$767K ﹤0.01% 3029
2025
Q1 		$7.27M Buy
832,788
+569,261
+216% +$7.18M ﹤0.01% 3392
2024
Q4 		$3.78M Buy
263,527
+18,773
+8% +$296K ﹤0.01% 4123
2024
Q3 		$5.53M Buy
244,754
+93,197
+61% +$1.93M ﹤0.01% 2975
2024
Q2 		$2.95M Buy
151,557
+97,290
+179% +$2.55M ﹤0.01% 3370
2024
Q1 		$2.04M Buy
54,267
+48,038
+771% +$2.11M ﹤0.01% 3943
2023
Q4 		$349K Sell
6,229
-4,882
-44% -$212K ﹤0.01% 5387
2023
Q3 		$458K Buy
11,111
+1,228
+12% +$63.9K ﹤0.01% 4729
2023
Q2 		$552K Sell
9,883
-12,589
-56% -$681K ﹤0.01% 4737
2023
Q1 		$1.25M Buy
22,472
+17,575
+359% +$821K ﹤0.01% 3899
2022
Q4 		$178K Buy
4,897
+3,029
+162% +$99K ﹤0.01% 5549
2022
Q3 		$53K Sell
1,868
-1,065
-36% -$40.6K ﹤0.01% 6308
2022
Q2 		$132K Sell
2,933
-21,008
-88% -$1.09M ﹤0.01% 5217
2022
Q1 		$1.82M Sell
23,941
-7,150
-23% -$625K ﹤0.01% 3522
2021
Q4 		$4.63M Buy
31,091
+2,049
+7% +$314K ﹤0.01% 2907
2021
Q3 		$4.23M Buy
29,042
+4,245
+17% +$729K ﹤0.01% 2854
2021
Q2 		$4.86M Sell
24,797
-5,530
-18% -$1M ﹤0.01% 2716
2021
Q1 		$5.49M Sell
30,327
-6,145
-17% -$1.06M ﹤0.01% 2495
2020
Q4 		$5.17M Sell
36,472
-27,980
-43% -$4.06M ﹤0.01% 2415
2020
Q3 		$8.04M Buy
64,452
+30,471
+90% +$3.2M ﹤0.01% 1803
2020
Q2 		$3.04M Buy
33,981
+5,622
+20% +$438K ﹤0.01% 2487
2020
Q1 		$1.77M Buy
28,359
+4,160
+17% +$325K ﹤0.01% 2869
2019
Q4 		$1.84M Buy
24,199
+23,162
+2,234% +$1.39M ﹤0.01% 3634
2019
Q3 		$52K Buy
+1,037
New +$57.4K ﹤0.01% 6180

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's TXG Position: Q2 2026 in Review

UBS Group increased its 10x Genomics (TXG) stake by 0.02% in Q2 2026, buying an estimated $2.78K and bringing the position to 494,868 shares worth $19M. The position accounts for ﹤0.01% of the portfolio, ranked #2742.

UBS Group first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • UBS Group held 494,868 shares of 10x Genomics worth $19M as of Q2 2026.
  • UBS Group bought 106 10x Genomics shares in Q2 2026, an estimated $2.78K.
  • 10x Genomics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2742 holding.
  • UBS Group first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.